Clinical Genetics Lacks Standard Definitions and Protocols for the Collection and Use of Diversity Measures

Alice B. Popejoy, Kristy Crooks, Stephanie M. Fullerton, Lucia A. Hindorff, Gillian W. Hooker, Barbara A. Koenig, Natalie Pino, Erin M. Ramos, Deborah Ritter, Hannah Wand, Matt W. Wright, Michael Yudell, James Zou, Sharon E. Plon, Carlos D. Bustamante, Kelly E. Ormond

TL;DR

A survey of 448 genetics professionals reveals a troubling lack of consensus on how to define and use race, ethnicity, and ancestry (REA) in clinical practice. Despite their critical role in precision medicine, these measures are often used inconsistently or as inaccurate proxies for one another, highlighting an urgent need for standardized clinical guidelines.

What Problem Does This Paper Address?

In the era of precision medicine, understanding a patient’s background is vital for interpreting genetic variants. For example, a rare mutation in one population might be common (and benign) in another. However, the field currently lacks a "common tongue" for diversity.

Researchers and clinicians frequently use the terms Race, Ethnicity, and Ancestry (REA), but these concepts are often conflated. Race and ethnicity are largely socio-cultural constructs reflecting environmental exposures and identity, while ancestry refers to the biological inheritance of genetic variants. When these are used interchangeably or without clear definitions, it can lead to inaccurate variant classifications, misleading clinical reports, and the exacerbation of health disparities. This paper investigates how professionals currently conceptualize and apply these measures in the real world.

Methods

The study utilized a cross-sectional survey design, developed through a partnership between two NIH-funded consortia: ClinGen and CSER.

  • Survey Validation: To ensure the 121-question instrument was robust, the authors conducted 11 "cognitive interviews" with target professionals to refine the language and logic.
  • Recruitment: The survey was disseminated via professional organizations (like ACMG and ASHG) and listservs, eventually employing a "snowball" approach to reach a broader network.
  • Analysis: Data from 448 respondents were analyzed using descriptive statistics. The researchers used branching logic to tailor questions to specific roles (e.g., lab directors vs. genetic counselors).

Datasets

The primary "dataset" for this study is the cohort of 448 survey respondents.

  • Composition: 60% were clinical professionals (geneticists, counselors, lab directors), 22% were non-clinical researchers, and the remainder were trainees or others.
  • Demographics: The sample was heavily North American (93%) and majority-white (71%), which the authors note is reflective of the current demographics of the genetics profession.

Key Insights and Ideas

  • The "Ancestry" Disconnect: While 66% of respondents agreed that "genetic lineage group" best describes ancestry, there is a massive gap between theory and practice. Ancestry was rated as the most important factor for variant interpretation, yet 85% of respondents reported that genetic ancestry is rarely or never actually calculated from a patient’s DNA in a clinical setting.
  • Proxies by Necessity: Because genetic ancestry data is rarely available, clinicians often rely on self-reported race or medical records as a proxy. The authors warn that this is scientifically problematic, especially for individuals with multi-ancestral backgrounds.
  • Heterogeneity of Thought: There was no single definition for "race" that a majority of participants agreed upon. Confidence in distinguishing between REA terms was significantly lower for "general" contexts than for "genetics-specific" contexts, suggesting that professionals feel they have a functional understanding that may not hold up under scrutiny.
  • The "It Depends" Factor: For many clinical scenarios, up to a third of respondents answered "I'm not sure" or "It depends" regarding the relevance of REA, indicating a high degree of uncertainty in how to apply this data to patient care.

Key Results

  • Usage: 94% of participants collect or use population identity information in their work.
  • Importance: Over 55% of respondents felt REA is important for clinical variant interpretation and ordering tests.
  • Clinical Motivation: 53% of professionals are more likely to discuss REA if the patient is from a racial or ethnic minority group, and 50% are motivated to do so when faced with a Variant of Uncertain Significance (VUS).
  • Consensus for Change: 65% of respondents explicitly stated that new, standardized guidelines for the collection and use of REA data are necessary for the field.

Limitations and Future Work

The study’s primary limitation is its geographic and demographic bias; the respondent pool was largely white and based in the U.S., which may not capture the perspectives of professionals in more diverse global regions. Additionally, the "snowball" recruitment method makes it difficult to calculate a precise response rate.

Future Work: The authors call for a multi-disciplinary effort—involving stakeholders from clinical labs, professional organizations, and patient advocacy groups—to develop a formal framework. This framework must move beyond using race as a proxy for biology and instead promote the use of validated genetic ancestry alongside socio-cultural data to ensure precision medicine is both accurate and equitable.

Summary updated

Abstract

Genetics researchers and clinical professionals rely on diversity measures such as race, ethnicity, and ancestry (REA) to stratify study participants and patients for a variety of applications in research and precision medicine. However, there are no comprehensive, widely accepted standards or guidelines for collecting and using such data in clinical genetics practice. Two NIH-funded research consortia, the Clinical Genome Resource (ClinGen) and Clinical Sequencing Evidence-generating Research (CSER), have partnered to address this issue and report how REA are currently collected, conceptualized, and used. Surveying clinical genetics professionals and researchers (n = 448), we found heterogeneity in the way REA are perceived, defined, and measured, with variation in the perceived importance of REA in both clinical and research settings. The majority of respondents (>55%) felt that REA are at least somewhat important for clinical variant interpretation, ordering genetic tests, and communicating results to patients. However, there was no consensus on the relevance of REA, including how each of these measures should be used in different scenarios and what information they can convey in the context of human genetics. A lack of common definitions and applications of REA across the precision medicine pipeline may contribute to inconsistencies in data collection, missing or inaccurate classifications, and misleading or inconclusive results. Thus, our findings support the need for standardization and harmonization of REA data collection and use in clinical genetics and precision health research.
BibTeX
@article{popejoy2020clinical,
  author = {Alice B. Popejoy and Kristy Crooks and Stephanie M. Fullerton and Lucia A. Hindorff and Gillian W. Hooker and Barbara A. Koenig and Natalie Pino and Erin M. Ramos and Deborah Ritter and Hannah Wand and Matt W. Wright and Michael Yudell and James Zou and Sharon E. Plon and Carlos D. Bustamante and Kelly E. Ormond},
  title = {{Clinical Genetics Lacks Standard Definitions and Protocols for the Collection and Use of Diversity Measures}},
  journal = {The American Journal of Human Genetics},
  year = {2020},
  doi = {10.1016/j.ajhg.2020.05.005},
}

Loading related content...

Figure